Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
about
The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer.Epigenetics: new possibilities for drug discovery.Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of CholangiocarcinomaGeneral Anesthesia and Young Brain: What is New?Epigenetics and Metabolism in Health and Disease
P2860
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Repositioning FDA-Approved Dru ...... rogram Colon Cancer Epigenome.
@ast
Repositioning FDA-Approved Dru ...... rogram Colon Cancer Epigenome.
@en
type
label
Repositioning FDA-Approved Dru ...... rogram Colon Cancer Epigenome.
@ast
Repositioning FDA-Approved Dru ...... rogram Colon Cancer Epigenome.
@en
prefLabel
Repositioning FDA-Approved Dru ...... rogram Colon Cancer Epigenome.
@ast
Repositioning FDA-Approved Dru ...... rogram Colon Cancer Epigenome.
@en
P2093
P2860
P1476
Repositioning FDA-Approved Dru ...... program Colon Cancer Epigenome
@en
P2093
Elodie M Da Costa
Hanghang Zhang
Justin T Lee
Noël J-M Raynal
Saira Ahmed
Takahiro Sato
Vazganush Gharibyan
P2860
P304
P356
10.1158/1535-7163.MCT-16-0588
P577
2016-12-15T00:00:00Z